Skye Bioscience Hosts Virtual KOL Event on CB1 Inhibition Metabolic Rewiring July 24th

SAN DIEGO, July 11, 2024 – Skye Bioscience, Inc. (Nasdaq: SKYE), a biotech company in the clinical stage, is dedicated to the innovation, development, and commercialization of new therapeutic drugs targeting the endocannabinoid system. The company has announced an upcoming virtual Key Opinion Leader (KOL) event titled “Metabolic Rewiring with CB1 Inhibition,” scheduled for Wednesday, July 24, 2024, at 9:00 AM ET.

The event will highlight leading experts in obesity treatment: Dr. Louis J. Aronne (Weill Cornell Medicine), Dr. Marcus DaSilva Goncalves (NYU Langone Health), Dr. Lee M. Kaplan (Geisel School of Medicine at Dartmouth), and Dr. Beverly Tchang (Weill Cornell Medicine). The speakers will delve into the current therapeutic landscape for obesity, emphasizing the significance of peripheral CB1 inhibition as a distinctive mechanism.

A central theme will be the scientific justification for Skye’s development of Nimacimab, a peripheral CB1 inhibitor. Discussions will cover clinical experiences and the design of the Phase 2 study for Nimacimab, both as a standalone treatment and in combination with a GLP-1R agonist. The Phase 2 trial is scheduled to commence dosing in Q3 2024.

The event will conclude with a question and answer session following the formal presentations. Participants must register in advance to join the webcast. For those unable to attend the live event, a replay will be available.

Dr. Louis Aronne is a renowned expert in obesity treatment, holding the position of Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medical College. He directs the Center for Weight Management and Metabolic Clinical Research and is also associated with Columbia University. He is the Founder and CEO of BMIQ, a weight control program, and has contributed over 60 academic papers and book chapters on obesity.

Dr. Marcus DaSilva Goncalves serves as an Associate Professor of Medicine and Director of Systemic Metabolism Research at NYU Langone Health. As a physician-scientist, he focuses on systemic pathways regulating body weight, muscle mass, and metabolism, with his lab working on innovative treatments for obesity, cachexia, and cancer. Additionally, as an endocrinologist, he treats patients dealing with obesity, diabetes, and endocrine complications related to cancer.

Dr. Lee Kaplan is a Professor of Medicine and Chief of the Division of Obesity Medicine at the Geisel School of Medicine at Dartmouth. He also directs the Dartmouth Weight and Wellness Center and chairs the U.S. Obesity Medicine Fellowship Council. Dr. Kaplan has authored over 250 research papers and has been instrumental in developing rodent models that enhance the understanding of clinical and genetic predictors of patient responses to various obesity therapies.

Dr. Beverly Tchang is a triple board-certified physician specializing in obesity medicine and holds an Assistant Professorship in Clinical Medicine at Weill Cornell. Since 2018, she has been treating patients and training professionals in endocrinology and obesity. Dr. Tchang's expertise has made her a sought-after advisor for companies and entrepreneurs focusing on modern weight management.

Nimacimab is a pioneering humanized monoclonal antibody designed to inhibit CB1 signaling peripherally. Inhibiting CB1 has shown promising anti-fibrotic, anti-inflammatory, and metabolic effects, potentially addressing diseases such as obesity, chronic kidney disease, and metabolic dysfunction-associated steatohepatitis (MASH).

Skye Bioscience is committed to exploring the pharmaceutical potential of the endocannabinoid system to treat various diseases involving metabolic, inflammatory, and fibrotic processes. Supported by expert life science investors, Skye’s approach targets biologic mechanisms with substantial human proof for developing first-in-class therapeutics. Skye is set to initiate a Phase 2 clinical trial in obesity for Nimacimab in Q3 2024, comparing its efficacy as a monotherapy and in conjunction with a GLP-1R agonist.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!